She sure did emphasize that. I wouldn't really expect anything else though, would you? At the end of the day these therapies will be in competition before they are used in combination. And that type of combo sure will be pricey for the next decade..
But anyway, checkpoint inhibitors have a much better safety profile than nearly all chemos. And for now, they really are the star of the immunotherapy show. Though I think there is enough theoretical evidence they will work much better in combination with DC therapy (and vice versa). I think that is the not too distant future. What you are talking about might be the distant future.
Here's what I think might happen in practice: a patient is treated with a DC vaccine (which I see becoming mainstream within 5-7 years) OR a chk. inh. Once they experience recurrence, they will then go on the other (I think DC first is better, btw). But then somewhere down the line, when generics pop up for chk. inh. and DC vaccines are all over the place, they will both be much cheaper and combo therapies involving the timing of integration of each will then become mainstream, imo. And it's here that I see the prognosis of most cancers truly dramatically changing to the positive. If NWBO isn't willing, Sotio will be, etc.
All musings of course. You may agree with me in a couple of years. Until then in never hurts to be a little too open minded, no? It's bound to happen: DCVax Direct + L + chk.inh. vs Direct +L alone.
$.02
News 
Market Data 
Discover 
